Rocuronium Bromide: A Comprehensive Pharmacological and Clinical Monograph

1.0 Executive Summary

Rocuronium is an aminosteroid, nondepolarizing neuromuscular blocking agent (NMBA) distinguished in modern anesthetic practice by its characteristically rapid onset of action and intermediate duration.[1] As a cornerstone of anesthesia, it is employed as an adjunct to general anesthesia to facilitate both routine and rapid sequence tracheal intubation (RSI), as well as to provide profound skeletal muscle relaxation during surgical procedures and for patients requiring mechanical ventilation.[3] Its primary clinical advantage lies in its ability to achieve intubating conditions at a speed comparable to the depolarizing agent succinylcholine, particularly when administered at higher doses, but with a more favorable and safer side-effect profile, establishing it as a critical alternative for RSI.[5]

A transformative development in the clinical use of rocuronium has been the introduction of sugammadex, a selective relaxant binding agent (SRBA). While the neuromuscular blockade induced by rocuronium can be partially reversed by traditional acetylcholinesterase inhibitors like neostigmine, sugammadex offers a unique mechanism that allows for rapid, complete, and reliable reversal of even deep levels of blockade.[1] This innovation has profoundly enhanced the safety profile and clinical utility of rocuronium, allowing for more aggressive dosing with a reliable safety net.[7]

The safety profile of rocuronium is generally favorable, demonstrating notable hemodynamic stability. However, it is associated with a significant risk of anaphylaxis, a rare but potentially fatal hypersensitivity reaction that necessitates constant vigilance and preparedness.[3] Furthermore, meticulous clinical management, including the use of neuromuscular monitoring, is mandatory to prevent the complication of postoperative residual neuromuscular blockade, which can lead to significant respiratory morbidity.[10]

2.0 Chemical and Physical Properties

2.1 Identification and Nomenclature

Rocuronium is a small molecule drug that exists as a cation in its active form. For pharmaceutical use, it is prepared and administered as the bromide salt, rocuronium bromide.[12] It is identified by several standardized codes across global databases and regulatory bodies, which are essential for accurate identification in clinical, research, and pharmaceutical contexts.

Key identifiers include:

• DrugBank ID: DB00728 [1]
• CAS Number: 143558-00-3 (for the rocuronium cation) and 119302-91-9 (for rocuronium bromide) [1]

The drug is known by numerous synonyms and trade names worldwide. It was originally developed under the investigational code ORG 9426.[1] Commercially, it is most commonly marketed under the brand names

Zemuron (primarily in the United States) and Esmeron or Esmerone in Europe and other regions.[1] A comprehensive list of synonyms includes chemical descriptors such as

1-(17-(acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium and (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane, among many others cataloged in databases like PubChem and MeSH.[1]

2.2 Molecular Structure and Formulation

Rocuronium is classified as a synthetic organic compound, specifically a monoquaternary aminosteroid neuromuscular blocker.[2] It is structurally derived from a 5alpha-androstane steroid nucleus and is a desacetoxy analogue of its predecessor, vecuronium.[1] The intricate molecular architecture of rocuronium is the result of deliberate chemical modifications designed to optimize its pharmacological profile, particularly its onset of action.

The key structural features include [1]:

• A 5alpha-androstane steroid backbone.
• A 3alpha-hydroxy group.
• A 17beta-acetoxy ester group.
• A 2beta-morpholino group.
• A 16beta-N-allyllyrrolidinium substituent, which forms the quaternary ammonium ion responsible for its neuromuscular blocking activity.

The specific chemical modifications to the steroid backbone, particularly the mono-quaternary structure and the presence of an allyl group on the quaternary nitrogen, were not arbitrary. They were the result of a targeted drug design strategy. The goal was to create a neuromuscular blocker with a weaker antagonist profile at the nicotinic receptor compared to the potent, long-acting agent pancuronium.[2] This seemingly counterintuitive approach—designing a weaker antagonist—is fundamental to its rapid onset. Weaker antagonism implies a lower binding affinity for the receptor. When a high concentration of a lower-affinity drug is delivered to the synapse, it can more rapidly occupy the large number of receptors required to achieve neuromuscular blockade, as the binding and unbinding kinetics are faster. This structural design choice, particularly the allyl and pyrrolidine groups, directly translates into rocuronium's most significant clinical advantage: speed.[2]

For clinical use, rocuronium is formulated as rocuronium bromide, an organic bromide salt, which is supplied as a sterile solution for intravenous administration.[12]

2.3 Synthesis

The synthesis of rocuronium bromide is a complex, multi-step process in organic chemistry, beginning with steroid precursors. The efficiency and purity of this synthesis are critical for the drug's commercial viability and safety. While several routes exist, recent advancements have focused on improving yield and minimizing impurities.[18]

Traditional synthesis routes typically involve the ring-opening of a 2α, 3α-epoxy steroid with morpholine after a 16β-pyrrolidinyl group has been introduced, but these methods often suffer from low yields.[18] A more modern and efficient synthetic pathway has been developed that significantly improves the process. This route begins with 5α-androstan-2-en-17-one and proceeds through several key transformations [18]:

1. Epoxidation: The double bond of the starting material is epoxidized using formic acid and hydrogen peroxide to form an epoxide intermediate.
2. Ring-Opening with Morpholine: The epoxide ring is opened via a Lewis acid-catalyzed reaction (using iron(III) chloride, FeCl3​) in the presence of morpholine to introduce the morpholino group at the 2β position.
3. Bromination: The intermediate is brominated at the 16α position using cupric bromide (CuBr2​).
4. Introduction of Pyrrolidine: The bromo group is substituted with pyrrolidine.
5. Reduction: The 17-keto group is reduced to a hydroxyl group using sodium borohydride (NaBH4​).
6. Acetylation and Quaternization: The final steps involve acetylation of the 17-hydroxyl group and quaternization of the pyrrolidine nitrogen with allyl bromide to form the final rocuronium bromide product.

This improved synthesis pathway offers two major advantages. First, it increases the overall yield of the key intermediate to 57.8%, which is a substantial improvement over previously reported methods.[18] This higher yield directly translates to lower manufacturing costs, a crucial factor for maintaining competitiveness in a market with increasing generic pressure.[20] Second, and perhaps more importantly from a safety perspective, this method avoids the generation of specific disubstituted impurities (designated E and F) that are difficult to remove in traditional processes.[18] Impurities in pharmaceutical products can lead to unpredictable adverse effects or diminished efficacy. Therefore, a cleaner synthesis process results in a purer, more reliable, and ultimately safer final drug product, which is of paramount importance for a high-risk medication used in the acute setting of anesthesia. A simplified process described in patent literature involves combining a late-stage precursor (Compound VIII) with allyl bromide in a polar aprotic organic solvent with an inorganic base to isolate the final product.[22]

Table 2.1: Chemical and Physical Properties of Rocuronium Bromide

Property	Value	Source(s)
IUPAC Name	phenanthren-17-yl] acetate;bromide	13
CAS Number	143558-00-3 (Cation); 119302-91-9 (Bromide Salt)	1
DrugBank ID	DB00728	1
Molecular Formula	C32​H53​BrN2​O4​	12
Molecular Weight	609.7 g/mol	13
Chemical Class	Aminosteroid; Nondepolarizing Neuromuscular Blocker	1
Key Structural Features	5α-androstane core, 3α-hydroxy, 17β-acetoxy, 2β-morpholino, 16β-N-allylpyrrolidinium	1
Hydrogen Bond Donor Count	1	13
Hydrogen Bond Acceptor Count	6	13
Rotatable Bond Count	6	13
Topological Polar Surface Area	59 A˚2	13

3.0 Pharmacology

3.1 Mechanism of Action

Rocuronium is classified as a nondepolarizing neuromuscular blocking agent.[1] Its primary mechanism of action is centered at the neuromuscular junction, the specialized synapse where motor neurons communicate with skeletal muscle fibers. Rocuronium functions as a

competitive antagonist at the nicotinic acetylcholine receptors (nAChRs) located on the motor end-plate, the postsynaptic membrane of the muscle fiber.[2]

Under normal physiological conditions, the neurotransmitter acetylcholine (ACh) is released from the nerve terminal, diffuses across the synaptic cleft, and binds to these nAChRs. This binding event opens ion channels, leading to a depolarization of the muscle cell membrane, which, if it reaches threshold, generates an action potential that propagates along the muscle fiber and triggers contraction.[23] Rocuronium exerts its effect by physically occupying the binding sites on the nAChRs, thereby preventing ACh from binding. Because rocuronium does not activate the receptor itself, it does not cause depolarization. Instead, it competitively inhibits the action of ACh, preventing the end-plate depolarization required for muscle contraction and resulting in a state of flaccid muscle paralysis.[16]

This competitive antagonism is surmountable and reversible. The neuromuscular blockade can be overcome by increasing the concentration of ACh at the neuromuscular junction. This is the principle behind the use of acetylcholinesterase inhibitors (e.g., neostigmine, edrophonium) as reversal agents. These drugs inhibit the enzyme that breaks down ACh, leading to an accumulation of ACh in the synaptic cleft. The elevated ACh concentration can then outcompete rocuronium for binding sites on the nAChRs, restoring neuromuscular transmission.[17]

In addition to its primary activity at the neuromuscular junction, rocuronium has been shown to have antagonist activity at other receptor sites, although the clinical significance of these interactions is less defined. These include the neuronal acetylcholine receptor subunit alpha-2 (nAChRα2​), the muscarinic acetylcholine receptor M2 (M2​), and the 5-hydroxytryptamine receptor 3A (5-HT3A).[8]

3.2 Pharmacodynamics

3.2.1 Onset and Duration of Action

The pharmacodynamic profile of rocuronium is characterized by a rapid to intermediate onset and an intermediate duration of action, both of which are highly dose-dependent.[24]

Onset of Action: The rapid onset is a key clinical feature that distinguishes rocuronium from many other nondepolarizing NMBAs. Following a standard intubating dose of 0.6 mg/kg, a neuromuscular block of 80% or greater is achieved in a median time of just 1 minute (range: 0.4-6 minutes), with most patients having conditions suitable for intubation within 2 minutes.[3] When higher doses are used for rapid sequence intubation (RSI), such as 0.9 mg/kg to 1.2 mg/kg, the onset is even faster, with adequate intubating conditions achieved within 60 to 90 seconds. This rapid onset makes rocuronium pharmacodynamically comparable to the depolarizing agent succinylcholine for RSI applications.[4]

Duration of Action: Rocuronium is classified as an intermediate-acting agent.[1] The clinical duration of relaxation is also dose-dependent. A standard 0.6 mg/kg dose provides a median of 31 minutes (range: 15-85 minutes) of clinical relaxation under opioid/nitrous oxide/oxygen anesthesia.[3] The duration is significantly prolonged with higher doses; for example, a 1.2 mg/kg dose can extend the duration to approximately 67 minutes.[5]

3.2.2 Dose-Response and Clinical Effect

The dose required to produce 95% suppression of the first twitch (T1) of a train-of-four (TOF) stimulation, known as the ED95, is approximately 0.3 mg/kg for rocuronium under opioid-based anesthesia.[25] Clinical studies have demonstrated that a dose of 0.6 mg/kg (approximately 2 x ED95) provides "excellent or good" intubating conditions in 96% of adult patients.[25]

Pharmacodynamic studies have also investigated muscle-specific sensitivity to rocuronium. For instance, one study was designed to characterize the dose-effect relationship at the adductor pollicis (a peripheral muscle commonly used for monitoring) and the masseter muscle (a central muscle relevant to jaw relaxation for intubation). The hypothesis was that the masseter muscle would exhibit greater sensitivity, a faster onset, and a slower recovery profile compared to the adductor pollicis, highlighting the complex and non-uniform effects of NMBAs across different muscle groups.[27]

3.2.3 Cardiovascular and Systemic Effects

Rocuronium is generally considered to have a stable cardiovascular profile, a significant advantage over some other NMBAs.[11] In clinical trials, there were no consistent, dose-related effects on mean arterial blood pressure (MAP) or heart rate at doses up to 1.2 mg/kg.[25] However, transient episodes of tachycardia and hypertension have been reported in approximately one-third of adult patients.[9] These hemodynamic changes are often attributed to the sympathetic stimulation associated with laryngoscopy and tracheal intubation rather than a direct pharmacological effect of the drug itself.[25]

Rocuronium has a very low propensity to cause histamine release. Clinical signs associated with histamine release, such as flushing, rash, or bronchospasm, are rare, having been reported in only 0.8% of patients in clinical trials.[9]

3.2.4 Reversal of Neuromuscular Blockade

The reversal of rocuronium-induced neuromuscular blockade is a critical aspect of its clinical use and can be achieved through two distinct mechanisms.

Acetylcholinesterase Inhibitors: Once spontaneous recovery of neuromuscular function has begun (typically defined as the return of the first twitch of a TOF to 25% of its baseline height, or T1 25%), the block can be readily and effectively reversed with acetylcholinesterase inhibitors such as neostigmine or edrophonium.[23] These agents increase the amount of acetylcholine at the neuromuscular junction, allowing it to compete more effectively with rocuronium for receptor binding sites.

Sugammadex (Bridion®): The introduction of sugammadex represents a paradigm shift in the management of neuromuscular blockade. Sugammadex is a modified gamma-cyclodextrin that functions as a selective relaxant binding agent (SRBA).[1] Instead of acting on the cholinergic system, it works by a novel mechanism of direct encapsulation. The sugammadex molecule has a hydrophobic core and a hydrophilic exterior, which allows it to selectively encapsulate the lipophilic steroid nucleus of rocuronium molecules in the plasma.[23] This binding is extremely strong and rapid. By sequestering free rocuronium in the plasma, sugammadex creates a steep concentration gradient that pulls rocuronium molecules off the nicotinic receptors at the neuromuscular junction and back into the plasma, where they are then encapsulated. This leads to a very rapid and complete reversal of the neuromuscular block, even from profound depths (i.e., no response to TOF stimulation).[23]

The availability of sugammadex has fundamentally altered the clinical pharmacology of rocuronium. Traditionally viewed as an "intermediate-duration" agent whose effects were dictated by its pharmacokinetic profile, rocuronium can now be transformed into a functionally "short-acting" agent when reversal is intended. The duration of action is no longer solely determined by its metabolic half-life but can be actively and predictably terminated by the clinician within minutes. This capability has made the combination of high-dose rocuronium (e.g., 1.2 mg/kg) followed by sugammadex reversal a direct and often safer competitor to succinylcholine for RSI, as the risk of prolonged paralysis in a "can't intubate, can't ventilate" scenario is significantly mitigated.[5]

3.3 Pharmacokinetics

3.3.1 ADME Profile

The disposition of rocuronium in the body is characterized by its intravenous administration, limited protein binding, and primary elimination through the liver.

• Absorption: As a quaternary ammonium compound, rocuronium is poorly absorbed from the gastrointestinal tract and must be administered intravenously to achieve its effect.[17]
• Distribution: Following IV administration, rocuronium undergoes rapid distribution. It has a rapid distribution half-life of 1-2 minutes and a slower distribution half-life of 14-18 minutes.[17] The volume of distribution at steady state ( Vdss​) in adults is approximately 0.25 L/kg.[25] Rocuronium is approximately 30% bound to human plasma proteins, indicating that a substantial fraction of the drug is free and available to act at the neuromuscular junction.[2]
• Metabolism: The liver is the primary site of rocuronium elimination.[17] The drug undergoes some degree of hepatic metabolism, primarily through de-acetylation at the 17-position of the steroid nucleus. This process forms the metabolite 17-desacetyl-rocuronium. This metabolite is significantly less active than the parent compound, possessing only about 5% of the neuromuscular blocking potency of rocuronium, and is therefore considered clinically insignificant at the concentrations typically achieved.[2]
• Excretion: Rocuronium is eliminated from the body primarily through biliary excretion, with a large portion of the unchanged drug being taken up by the liver and excreted into the bile.[29] Animal studies have shown that up to 70% of an administered dose can be recovered in the feces.[30] A smaller but still significant portion, up to 33% of the dose, is excreted unchanged in the urine within 12-24 hours.[2] Rocuronium is also a known substrate for the solute carrier transporters SLCO1A2 (OATP1A2) and SLC22A1 (OCT1), which may play a role in its hepatic uptake and disposition.[14]

3.3.2 Pharmacokinetics in Special Populations

The pharmacokinetic profile of rocuronium can be significantly altered in various patient populations, which has direct implications for dosing and clinical management. The duration of action is primarily determined by the drug's clearance, and any physiological or pathological state that impairs clearance will prolong its effects.

• Pediatrics: There are notable differences between pediatric age groups. Clearance is higher and the mean residence time is significantly shorter in children (e.g., 25.6 minutes) compared to infants (e.g., 55.6 minutes). This means that rocuronium is longer-acting in infants than in children.[17] This pattern highlights that drug dosing cannot be simply scaled by weight across all pediatric populations; age-related differences in metabolic capacity and organ function must be considered.
• Geriatrics: In elderly patients (≥65 years), clearance is reduced (0.21 L/kg/hr vs. 0.25 L/kg/hr in younger adults) and the mean residence time is prolonged.[25] This leads to a significantly longer duration of action and recovery time, even though the onset of action may be similar to that in younger adults. This is a direct consequence of the age-related decline in hepatic and renal function.[30]
• Renal Impairment: In patients with end-stage renal failure, the clearance of rocuronium is reduced by approximately 39%.[29] While the volume of distribution remains unaffected, this reduction in clearance leads to a clinically significant prolongation of the drug's effect. The clinical duration and time to recovery can be extended by 50-60% compared to patients with normal renal function.[29]
• Hepatic Impairment: Given that the liver is the primary route of elimination, hepatic dysfunction has a profound impact on rocuronium's pharmacokinetics. In patients with impaired liver function, the elimination half-life is nearly doubled, and clearance is significantly reduced.[11] This results in a markedly prolonged duration of neuromuscular blockade, necessitating extreme caution and careful dose titration in this population.[26]
• Obesity: Rocuronium is a hydrophilic (low lipophilicity) compound, meaning it does not readily distribute into adipose (fat) tissue.[32] Its volume of distribution correlates more closely with lean body mass than with total body weight. Consequently, dosing rocuronium based on a patient's total body weight (TBW) can lead to a relative overdose, resulting in a higher plasma concentration and a significantly prolonged duration of action.[33] Therefore, clinical guidelines recommend calculating the dose based on ideal body weight (IBW) to avoid overdosing and minimize the risk of prolonged paralysis.[33]

Table 3.1: Summary of Pharmacokinetic Parameters in Key Populations

Parameter	Adult (27-58 yrs)	Geriatric (≥65 yrs)	Renal Failure	Hepatic Dysfunction	Pediatric (3-8 yrs)
Clearance (Cl)	0.25 L/kg/hr	0.21 L/kg/hr	Reduced by ~39%	0.13 L/kg/hr	0.44 L/kg/hr
Volume of Distribution (Vdss​)	0.25 L/kg	0.22 L/kg	Unaffected	Unchanged	0.21 L/kg
Elimination Half-life (t1/2​)	1.4 hr	1.5 hr	Prolonged	Almost Doubled	Shorter than adults
Mean Residence Time (MRT)	71.2 min	94.4 min	Increased by 84%	Prolonged	Shorter than infants
Clinical Implication	Standard duration	Prolonged duration	Prolonged duration	Markedly prolonged duration	Shorter duration
Sources: 17

4.0 Clinical Applications and Administration

4.1 Approved Indications

Rocuronium bromide is a versatile neuromuscular blocking agent approved for a range of clinical applications in both inpatient and outpatient settings. Its primary role is as an adjunct to general anesthesia. The approved indications are [3]:

• Facilitation of Tracheal Intubation: Rocuronium is indicated for facilitating both routine endotracheal intubation and rapid sequence induction (RSI) of anesthesia. Its rapid onset makes it particularly suitable for RSI, a procedure used to secure the airway quickly in patients at high risk of aspiration.
• Skeletal Muscle Relaxation: It is used to provide profound skeletal muscle relaxation during surgical procedures. This paralysis prevents patient movement and improves operating conditions for the surgeon, particularly in abdominal and thoracic surgery.
• Facilitation of Mechanical Ventilation: Rocuronium is used to facilitate mechanical ventilation in patients who are "fighting the ventilator" or require deep paralysis to improve gas exchange and reduce oxygen consumption. This is a common application in the Intensive Care Unit (ICU).

These indications apply to a broad patient population, including adults and pediatric patients from term newborn infants to adolescents.[4] Additionally, in some jurisdictions, rocuronium is used as part of the drug regimen for medical assistance in dying.[2]

4.2 Dosing and Administration

The dosing of rocuronium must be carefully individualized based on the clinical indication, patient characteristics (age, weight, organ function), and concomitant medications. The use of a peripheral nerve stimulator to monitor neuromuscular function is considered mandatory for safe administration.[3]

4.2.1 Intubation Dosing

• Routine Tracheal Intubation: For adults and pediatric patients over 14 years of age, the standard intubating dose is 0.6 mg/kg administered intravenously.[3] A lower dose of 0.45 mg/kg may also be used, though it provides a shorter duration of relaxation and may not achieve the same quality of intubating conditions.[3]
• Rapid Sequence Intubation (RSI): For adults, a dose range of 0.6 mg/kg to 1.2 mg/kg IV is approved.[3] However, a critical distinction exists between the approved range and optimal clinical practice. Comparative studies and recent guidelines indicate that to achieve an onset of action and intubating conditions comparable to succinylcholine, a dose at the higher end of this range, specifically 0.9 mg/kg to 1.2 mg/kg, is necessary.[5] The use of a 0.6 mg/kg dose for RSI results in a slower onset and may provide inferior intubating conditions compared to succinylcholine.[6] The confidence provided by the availability of sugammadex for rapid reversal has made clinicians more comfortable using these higher, more effective doses for RSI.
• Pediatric Intubation (3 months - 14 years): The recommended initial dose is 0.6 mg/kg IV.[34] The use of rocuronium for RSI in the pediatric population is not recommended by some sources, reflecting a more cautious approach in this group.[35]

4.2.2 Maintenance of Neuromuscular Blockade

Once intubation is achieved, neuromuscular blockade can be maintained for the duration of the surgical procedure using either intermittent bolus doses or a continuous infusion.

• Intermittent Bolus Dosing: Maintenance doses of 0.1 mg/kg to 0.2 mg/kg IV are typically administered when there is evidence of returning neuromuscular function. This is guided by neuromuscular monitoring, with doses given when the twitch height has recovered to 25% of the control value or when 2-3 responses to a train-of-four (TOF) stimulation are present.[3]
• Continuous Infusion: For longer procedures, a continuous infusion provides a more stable level of paralysis. It is recommended to begin with a loading dose (e.g., 0.6 mg/kg) and start the infusion only after early evidence of spontaneous recovery.[3] The initial infusion rate is typically 10-12 mcg/kg/min (equivalent to 0.6-0.72 mg/kg/hr) and must be individualized for each patient by titrating the rate to the twitch response.[3] When potent inhalational anesthetics are used, which potentiate the block, the infusion rate should be reduced by approximately 40%, to a range of 0.3-0.4 mg/kg/hr.[4]

4.2.3 Dosing in Special Populations

• Geriatric, Hepatic, and Renal Failure Patients: The standard intubating dose of 0.6 mg/kg is generally used. However, because clearance is reduced in these populations, clinicians must anticipate a significantly prolonged duration of action. Maintenance doses should be smaller and administered less frequently, guided carefully by neuromuscular monitoring.[4]
• Obese Patients: This population requires a specific dosing strategy based on the drug's pharmacokinetic properties. As rocuronium is hydrophilic and does not distribute extensively into fat, dosing should be calculated based on ideal body weight (IBW), not total body weight (TBW).[26] Using TBW would result in a relative overdose, leading to unnecessarily deep and prolonged paralysis. Studies suggest that IBW-based dosing provides comparable intubating conditions to TBW-based dosing but with a more predictable and shorter duration of paralysis.[32]
• Caesarean Section: For patients undergoing Caesarean section, a dose of 0.6 mg/kg is recommended. The higher 1.0 mg/kg dose has not been investigated in this patient group and should be avoided.[4]

4.3 Clinical Monitoring and Administration

Safe and effective use of rocuronium is critically dependent on appropriate monitoring and administration techniques.

• Neuromuscular Monitoring: Continuous monitoring of neuromuscular function using a peripheral nerve stimulator is mandatory. Techniques such as train-of-four (TOF) stimulation are used to assess the depth of the blockade, guide the timing of maintenance doses, and, most importantly, confirm adequate recovery of muscle function before tracheal extubation. The Society for Airway Management and other professional bodies consider this the standard of care to prevent postoperative residual paralysis.[3] Additional doses of rocuronium should not be administered until there is a definite response to nerve stimulation (e.g., at least one twitch in a TOF count).[26]
• Administration: Rocuronium is administered intravenously only. It can be given as a rapid bolus injection or as a continuous infusion using a calibrated infusion pump. It is compatible with common intravenous solutions, including 5% Dextrose in Water (D5W), Normal Saline (NS), and Lactated Ringer's (LR) solution. Infusion solutions should be prepared by mixing rocuronium with an appropriate diluent and used within 24 hours.[3]

Table 4.1: Recommended Dosing and Administration Regimens for Rocuronium

Clinical Indication	Patient Population	Recommended Dose / Rate	Source(s)
Routine Intubation	Adult / Peds >14 yrs	0.45 - 0.6 mg/kg IV bolus	3
	Pediatric (3 mo - 14 yrs)	0.6 mg/kg IV bolus	34
Rapid Sequence Intubation (RSI)	Adult	0.6 - 1.2 mg/kg IV bolus (0.9-1.2 mg/kg recommended for optimal conditions)	3
Maintenance (Bolus)	Adult	0.1 - 0.2 mg/kg IV, guided by TOF monitoring	3
	Pediatric (3 mo - 14 yrs)	0.075 - 0.125 mg/kg IV, guided by TOF monitoring	36
Maintenance (Infusion)	Adult (IV Anesthesia)	10 - 12 mcg/kg/min (0.6 - 0.72 mg/kg/hr), titrated to TOF	3
	Adult (Inhalational Anesthesia)	Rate reduced by ~40% (e.g., 0.3 - 0.4 mg/kg/hr)	4
Dosing in Obesity	All Indications	Calculate dose based on Ideal Body Weight (IBW)	26
Dosing in Geriatric / Renal / Hepatic Impairment	All Indications	Standard intubating dose (0.6 mg/kg), but anticipate prolonged duration. Use smaller, less frequent maintenance doses.	4

5.0 Safety and Tolerability

5.1 Adverse Effects

Rocuronium is generally well-tolerated, but it is associated with a range of adverse effects, from common, transient hemodynamic changes to rare but life-threatening events.

• Common/Uncommon Effects: The most frequently reported adverse reactions in clinical trials are transient hypotension and hypertension, each occurring in approximately 2% of patients.[9] Other less common effects, reported in less than 1% of patients, include cardiovascular events like arrhythmia and tachycardia, digestive issues such as nausea and vomiting, respiratory effects like hiccups and asthma-like symptoms (bronchospasm, wheezing), and skin reactions including rash and pruritus at the injection site.[9]
• Rare/Serious Effects: More serious adverse events, though rare, are of significant clinical concern. These include prolonged neuromuscular blockade (residual paralysis), which can manifest as ongoing muscle weakness, loss of movement, difficulty swallowing, and respiratory compromise post-extubation.[10] Severe respiratory events such as bronchospasm have also been reported.[38]

5.2 Warnings and Precautions

The use of rocuronium requires strict adherence to several critical warnings and precautions to ensure patient safety. The most significant safety concerns are not related to direct organ toxicity but rather to the potential for iatrogenic harm from mismanaged paralysis or severe allergic reactions.

• Anaphylaxis: Severe, life-threatening, and occasionally fatal anaphylactic and anaphylactoid reactions have been reported with rocuronium and other NMBAs.[3] The risk of an allergic reaction may be higher in patients with a history of asthma.[1] Crucially, allergic cross-reactivity exists among NMBAs. Therefore, it is essential to obtain a patient's history regarding previous allergic reactions to any neuromuscular blocking agent before administration.[3] Due to the potential severity of these reactions, appropriate emergency treatment (e.g., epinephrine, antihistamines, corticosteroids, and airway support) must be immediately available whenever rocuronium is used.[10]
• Residual Neuromuscular Blockade: This is a major safety concern and a significant cause of postoperative morbidity. Incomplete reversal of neuromuscular blockade can lead to muscle weakness, impaired respiratory function, hypoxia, and an increased risk of pulmonary aspiration.[11] To mitigate this risk, continuous neuromuscular monitoring with a peripheral nerve stimulator is considered the standard of care. It is essential to confirm adequate recovery of neuromuscular function (e.g., a TOF ratio >0.9) before tracheal extubation.[10]
• Myopathy: Prolonged administration of rocuronium, particularly via continuous infusion in the ICU, has been associated with the development of prolonged paralysis and/or acute myopathy (ICU-acquired weakness). The risk is substantially increased with concomitant use of corticosteroids.[9] The duration of paralysis should be limited as much as possible, and the benefits versus risks should be carefully considered for long-term use.
• Malignant Hyperthermia (MH): Although rocuronium is not a classic triggering agent for MH like succinylcholine, there have been postmarketing reports of MH occurring with its use.[9] Anesthesiologists and clinical facilities must be familiar with the early signs of MH and have a protocol and necessary supplies (e.g., dantrolene) for its immediate treatment.
• FDA Black Box Warning: It is important to note that rocuronium does not carry an FDA black box warning. This distinguishes it from certain other drug classes, such as fluoroquinolone antibiotics, which have received such warnings for risks like tendon rupture.[41] The absence of a black box warning does not diminish the severity of the known risks but places them in the context of standard warnings and precautions.[11]
• Special Patient Conditions: Caution is warranted in several patient populations. Patients with cardiovascular disease or advanced age may have slower circulation times, leading to a delayed onset of action.[10] Patients with neuromuscular diseases like myasthenia gravis or Eaton-Lambert syndrome can experience profound and prolonged effects from even small doses.[35] Significant hepatic disease will prolong the drug's duration due to impaired clearance.[10] Severe electrolyte imbalances (e.g., hypokalemia, hypocalcemia, hypermagnesemia) can also alter a patient's sensitivity to the drug.[10]

5.3 Drug Interactions

The drug interaction profile for rocuronium is extensive and dominated by pharmacodynamic interactions that occur at the neuromuscular junction. Clinicians must consider a patient's entire perioperative medication regimen to accurately predict the response to rocuronium and adjust dosing accordingly.

5.3.1 Potentiation of Neuromuscular Blockade

Numerous drugs can enhance or prolong the neuromuscular blocking effect of rocuronium, increasing the risk of prolonged paralysis.

• Inhaled Anesthetics: Potent volatile anesthetics are well-known potentiators of nondepolarizing NMBAs. The order of potentiation is generally enflurane and isoflurane > halothane.[43] These agents can prolong the duration of action of rocuronium and reduce the required maintenance infusion rate by up to 40% compared to intravenous anesthesia techniques.[4]
• Antibiotics: A number of antibiotics can enhance the neuromuscular blockade. This interaction is particularly well-documented for aminoglycosides (e.g., gentamicin, tobramycin), but also occurs with vancomycin, tetracyclines, polymyxins, colistin, and bacitracin. Co-administration can lead to prolonged respiratory depression and may require dose reduction and careful monitoring.[15]
• Other Drugs: Several other medications can potentiate the block, including magnesium salts (especially when used for pre-eclampsia), lithium carbonate, local anesthetics when administered systemically (e.g., lidocaine), procainamide, and calcium channel blockers such as amlodipine and clevidipine.[39]

5.3.2 Attenuation of Neuromuscular Blockade (Resistance)

• Chronic Anticonvulsants: Patients on long-term therapy with certain anticonvulsants, notably phenytoin and carbamazepine, may develop resistance to rocuronium. This manifests as a requirement for higher doses to achieve adequate blockade and a shorter duration of action. The likely mechanism is an upregulation of acetylcholine receptors at the neuromuscular junction in response to chronic anticonvulsant use.[44]

5.3.3 Other Pharmacodynamic Interactions

• CNS Depressants: When used as part of a general anesthetic, rocuronium is co-administered with other CNS depressants like opioids, benzodiazepines, and propofol. These agents have additive sedative and respiratory depressant effects.[10]
• Cholinergic and Anticholinergic Agents: Drugs that increase cholinergic activity, such as acetylcholinesterase inhibitors (e.g., neostigmine, donepezil) and cholinergic agonists (e.g., bethanechol), will antagonize the neuromuscular block.[14] Conversely, drugs with anticholinergic properties (e.g., atropine, aclidinium) may have additive anticholinergic side effects (e.g., tachycardia, dry mouth) when used with rocuronium.[14]
• Corticosteroids: The concomitant use of corticosteroids and rocuronium, especially over prolonged periods in the ICU, significantly increases the risk of developing acute myopathy and prolonged muscle weakness.[36]

Table 5.1: Clinically Significant Drug Interactions with Rocuronium

Interacting Drug/Class	Effect on Rocuronium Blockade	Mechanism of Interaction	Clinical Management Recommendation	Source(s)
Inhaled Anesthetics (e.g., Isoflurane, Enflurane)	Potentiation	Enhanced sensitivity of the postjunctional membrane; decreased motor neuron excitability.	Reduce maintenance doses/infusion rates of rocuronium by up to 40%. Monitor neuromuscular function closely.	4
Antibiotics (Aminoglycosides, Vancomycin, Tetracyclines)	Potentiation	Pre-junctional inhibition of acetylcholine release and post-junctional stabilization of the receptor.	Use with caution. Anticipate prolonged blockade. Monitor neuromuscular function closely and be prepared for prolonged ventilation.	15
Chronic Anticonvulsants (Phenytoin, Carbamazepine)	Attenuation (Resistance)	Upregulation of acetylcholine receptors at the neuromuscular junction.	Higher doses of rocuronium may be required. Anticipate a shorter duration of action. Guide dosing with neuromuscular monitoring.	44
Magnesium Salts	Potentiation	Decreased pre-junctional acetylcholine release and decreased excitability of the muscle membrane.	Use with extreme caution, especially in patients with toxemia of pregnancy. Reduce rocuronium dose and monitor closely.	39
Corticosteroids	Potentiation (risk of myopathy)	Not fully understood; may involve direct effects on muscle fibers and receptors.	Avoid prolonged co-administration, especially in the ICU. Monitor for signs of myopathy and muscle weakness.	36
Acetylcholinesterase Inhibitors (e.g., Neostigmine)	Antagonism (Reversal)	Increased acetylcholine concentration at the neuromuscular junction, which competes with rocuronium.	Used therapeutically to reverse neuromuscular blockade. Administer only after evidence of spontaneous recovery.	14
Calcium Channel Blockers (e.g., Amlodipine)	Potentiation	Interference with calcium influx required for acetylcholine release.	Use with caution. Monitor for enhanced neuromuscular blockade.	47

6.0 Comparative Analysis

The clinical utility of rocuronium is best understood by comparing it to other commonly used neuromuscular blocking agents, particularly the depolarizing agent succinylcholine and its fellow aminosteroid, vecuronium.

6.1 Rocuronium vs. Succinylcholine (Depolarizing Agent)

This comparison is central to the discussion of rapid sequence intubation (RSI).

• Mechanism of Action: The two drugs operate via fundamentally different mechanisms. Rocuronium is a competitive antagonist, blocking the nAChR without activating it (nondepolarizing).[2] Succinylcholine, being structurally similar to two linked acetylcholine molecules, is a receptor agonist. It binds to and activates the nAChR, causing an initial depolarization that manifests as visible muscle fasciculations, followed by a state of persistent depolarization that renders the muscle membrane unresponsive to further stimulation, leading to paralysis.[6]
• Onset of Action: For decades, succinylcholine's onset of 45-60 seconds was the undisputed gold standard for RSI.[6] However, when rocuronium is dosed at the higher end of its range (1.2 mg/kg), its onset time becomes comparable to that of succinylcholine, effectively eliminating succinylcholine's speed advantage.[6] At lower doses (0.6 mg/kg), rocuronium is significantly slower.[37]
• Duration of Action: This is a major point of differentiation. Succinylcholine has an ultra-short duration of action (4-10 minutes), as it is rapidly metabolized by plasma pseudocholinesterase.[6] Rocuronium has a much longer, intermediate duration (30-90 minutes, depending on dose).[6] Historically, succinylcholine's short duration was seen as a safety feature in a "can't intubate, can't ventilate" scenario, as spontaneous respiration would return quickly.
• Side Effect Profile: Rocuronium possesses a significantly more favorable safety profile. Succinylcholine is associated with a host of dangerous side effects, including life-threatening hyperkalemia (making it contraindicated in patients with burns, crush injuries, spinal cord injuries, and neuromuscular diseases), a higher risk of triggering malignant hyperthermia, and potential for severe bradycardia, especially in children.[6] Rocuronium avoids these specific risks, though it is associated with a higher incidence of anaphylactic reactions.[6]
• Reversal: The advent of sugammadex has revolutionized this comparison. Succinylcholine has no reversal agent; recovery is entirely dependent on the patient's enzymatic activity.[6] In contrast, the profound and prolonged block from a high dose of rocuronium can be rapidly and reliably reversed within minutes by sugammadex.[23]

The choice between rocuronium and succinylcholine for RSI once represented a clear trade-off: speed and short duration (succinylcholine) versus a better safety profile (rocuronium). The development of high-dose rocuronium protocols combined with the availability of sugammadex has largely mitigated this trade-off. Clinicians can now achieve the speed of succinylcholine with the superior safety profile of rocuronium, with the added benefit of a reliable reversal agent. This has led to a paradigm shift where high-dose rocuronium is increasingly considered a first-line agent for RSI, particularly in emergency settings where a patient's comorbidities and risk factors for succinylcholine may be unknown.[5]

6.2 Rocuronium vs. Vecuronium (Aminosteroid Analogue)

This comparison highlights the subtle but clinically significant differences between two structurally related drugs.

• Potency and Onset: Vecuronium is approximately six times more potent than rocuronium.[50] This difference in potency is directly linked to their difference in onset time. Rocuronium, being less potent, requires a larger number of molecules to be administered to achieve the same degree of receptor occupancy. This larger initial dose creates a steeper concentration gradient between the plasma and the neuromuscular junction, driving the drug to its site of action more quickly. This "large dose/low potency" principle explains why rocuronium has a much faster onset (~62 seconds) compared to vecuronium (~139 seconds).[50] This makes rocuronium suitable for RSI, whereas vecuronium is not.
• Hemodynamic Stability: Both drugs are known for their excellent cardiovascular stability. However, some comparative studies suggest that rocuronium is exceptionally stable, while vecuronium can be associated with a more significant, though often clinically minor, decrease in heart rate and mean arterial pressure.[51]
• Metabolism and Duration: As aminosteroid analogues, both are primarily metabolized by the liver and have an intermediate duration of action.[17] Some studies have found the duration of rocuronium to be slightly shorter than that of vecuronium.[51]
• Reversal: Both rocuronium and vecuronium can be reversed by acetylcholinesterase inhibitors and, more effectively, by sugammadex. However, the binding affinity of sugammadex is significantly higher for rocuronium than for vecuronium, making reversal from rocuronium-induced blockade more rapid and efficient.

The comparison between rocuronium and vecuronium provides a clear illustration of a fundamental pharmacological principle: the structure-activity relationship that links lower potency to a more rapid onset of action. For routine surgical relaxation where a rapid onset is not critical, both drugs are excellent choices. However, for any situation requiring rapid airway control, rocuronium's pharmacodynamic profile makes it the superior agent of the two.

Table 6.1: Comparative Profile: Rocuronium vs. Vecuronium vs. Succinylcholine

Feature	Rocuronium	Vecuronium	Succinylcholine
Class	Nondepolarizing (Aminosteroid)	Nondepolarizing (Aminosteroid)	Depolarizing
Mechanism	Competitive nAChR Antagonist	Competitive nAChR Antagonist	nAChR Agonist
Onset Time	Rapid (60-90s at 1.2 mg/kg)	Intermediate (120-180s)	Ultra-rapid (45-60s)
Duration	Intermediate (30-90 min)	Intermediate (30-60 min)	Ultra-short (4-10 min)
Potency	Low (1x)	High (~6x Rocuronium)	Low
Primary Elimination	Hepatic (Biliary) > Renal	Hepatic (Biliary) > Renal	Plasma Pseudocholinesterase
Key Side Effects	Anaphylaxis, transient tachycardia/hypertension	Minimal hemodynamic effects	Hyperkalemia, Malignant Hyperthermia, Fasciculations, Bradycardia
Reversal Agent	Sugammadex, Neostigmine	Sugammadex, Neostigmine	None
Primary Use Case	RSI, Routine relaxation, ICU	Routine relaxation, ICU	RSI (where not contraindicated)
Sources: 2

7.0 Regulatory and Commercial Landscape

7.1 Approval History

The regulatory history of rocuronium and its specific reversal agent, sugammadex, provides a compelling narrative of pharmaceutical development, safety evaluation, and the evolution of clinical practice.

• Rocuronium: Rocuronium was first introduced to the market in 1994.[1] The U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA 20-214) for the brand name product Zemuron™ on March 17, 1994.[53] This approval marked the arrival of a new nondepolarizing agent designed specifically for a rapid onset of action.
• Sugammadex (Bridion®): The story of rocuronium in the modern era is inextricably linked to the regulatory journey of its reversal agent. The development of sugammadex promised to solve rocuronium's main drawback for RSI—its long duration of action. However, its path to approval in the United States was long and arduous. Following its initial submission in 2007, the FDA rejected the application multiple times over eight years, citing concerns primarily related to the risk of hypersensitivity/anaphylactic reactions and potential effects on coagulation.[28] The manufacturer, Merck, was required to conduct extensive additional studies to address these safety concerns.[28] Finally, after a thorough review of new data and extensive postmarketing experience from Europe (where it was approved in 2008), the FDA granted approval for sugammadex on December 15, 2015.[2]

The eventual approval of sugammadex was a watershed moment. It was not merely the approval of a new drug but the validation of a novel pharmacological concept—selective relaxant binding. This approval fundamentally upgraded the safety and clinical utility of rocuronium, unlocking its full potential as a premier agent for RSI by providing an unparalleled safety net for rapid and reliable reversal.

7.2 Manufacturers and Market Presence

• Branded and Generic Landscape: Rocuronium was originally developed by Organon under the code ORG 9426 and has been marketed by Merck & Co. under the brand name Zemuron.[1] Pfizer also lists rocuronium bromide as one of its products.[55] Following the expiration of its patent, the market has seen the entry of numerous generic manufacturers. Companies such as Hikma Pharmaceuticals, Fresenius Kabi, Sandoz, Teva Pharmaceutical Industries, and Mylan now produce generic rocuronium bromide, which has significantly increased market competition and applied downward pressure on pricing.[20]
• Market Position and Sales: Despite generic competition, rocuronium remains a dominant neuromuscular blocking agent in the global anesthetics market. Its unique combination of rapid onset and an improved safety profile compared to succinylcholine secures its strong clinical position. As of 2023, rocuronium bromide generated approximately $300 million in annual global sales, reflecting its steady and essential role in hospitals, ambulatory surgical centers, and emergency departments.[20] Its faster onset gives it a distinct clinical edge over other nondepolarizing agents for emergency applications, helping it to maintain a significant market share.[20]

8.0 Conclusion and Expert Recommendations

Rocuronium bromide stands as a highly effective, versatile, and indispensable nondepolarizing neuromuscular blocking agent in the armamentarium of modern anesthesia and critical care. Its meticulously designed pharmacological profile, defined by a rapid onset of action and intermediate duration, makes it suitable for a wide spectrum of clinical scenarios, from routine surgical relaxation to the high-stakes environment of rapid sequence intubation. The clinical value and safety of rocuronium have been profoundly amplified by the development and approval of its specific reversal agent, sugammadex. This combination provides a level of control and predictability over neuromuscular blockade that was previously unattainable, solidifying rocuronium's position as a premier choice for ensuring patient safety and optimizing procedural conditions.

Based on a comprehensive analysis of its properties and clinical use, the following expert recommendations are put forth to guide its safe and effective application:

• Embrace Individualized Dosing: Clinicians must move beyond a "one-size-fits-all" approach to dosing. It is imperative to individualize therapy based on a careful assessment of patient-specific factors, including age, renal function, and hepatic function, as well as the specific clinical context (e.g., RSI vs. routine surgery, use of volatile anesthetics). For obese patients, dosing based on ideal body weight (IBW) is a critical practice to prevent relative overdosing and prolonged paralysis.
• Uphold Mandatory Neuromuscular Monitoring: The use of a peripheral nerve stimulator for continuous neuromuscular monitoring should be considered non-negotiable. It is the definitive standard of care required to accurately guide the administration of maintenance doses, prevent the catastrophic complication of intraoperative awareness, and, most importantly, ensure the complete reversal of blockade before extubation to mitigate the significant risks of postoperative residual paralysis.
• Maintain Situational Awareness of Drug Interactions: The pharmacodynamic profile of rocuronium is highly susceptible to alteration by concomitant medications. A thorough review of a patient's medication list is essential before administration. Clinicians must be prepared to anticipate and manage potential interactions—such as the potentiation caused by certain antibiotics and volatile anesthetics or the resistance induced by chronic anticonvulsant therapy—to ensure a predictable and safe course of neuromuscular blockade.
• Leverage the Rocuronium-Sugammadex System: The availability of sugammadex should not be viewed as a rescue option but as an integral part of the rocuronium "system." Its existence allows for the confident and effective use of higher, more reliable doses of rocuronium for RSI, while providing an unparalleled safety net for rapid and complete reversal. This system should be leveraged strategically to improve patient safety and outcomes, particularly in unpredictable airway management scenarios.
• Maintain Vigilance for Anaphylaxis: While rare, the risk of a severe anaphylactic reaction to rocuronium is real and potentially fatal. Anesthesiologists must maintain a high index of suspicion for any signs of a hypersensitivity reaction following administration and must be prepared for the immediate and aggressive management of anaphylaxis according to established protocols.

Works cited

1. Rocuronium | C32H53N2O4+ | CID 441290 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Rocuronium
2. Rocuronium bromide - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Rocuronium_bromide
3. These highlights do not include all the information ... - Baxter PI, accessed July 21, 2025, https://baxterpi.com/pi-pdf/Rocuronium%20Bromide%20PI.pdf
4. RocuroniumBromideMedsurgeinj.pdf - NEW ZEALAND DATA SHEET, accessed July 21, 2025, https://www.medsafe.govt.nz/profs/datasheet/r/RocuroniumBromideMedsurgeinj.pdf
5. What is the intubating dose of Rocuronium (rocuronium)? - Dr.Oracle, accessed July 21, 2025, https://www.droracle.ai/articles/63820/intubating-dose-of-rocuronium
6. Succinylcholine vs. Rocuronium: Battle of the RSI Paralytics - JEMS, accessed July 21, 2025, https://www.jems.com/patient-care/airway-respiratory/succinylcholine-vs-rocuronium-battle-of-the-rsi-paralytics/
7. rocuronium | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 21, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4003
8. ROCURONIUM (PD010055, YXRDKMPIGHSVRX-OOJCLDBCSA-N) - Probes & Drugs, accessed July 21, 2025, https://www.probes-drugs.org/compound/PD010055/
9. Rocuronium bromide (NDC 0409-9558-05 and 0409-9558-10) (rocuronium bromide) Adverse Reactions, accessed July 21, 2025, https://www.pfizermedicalinformation.com/rocuronium-bromide-injection/adverse-reactions
10. Rocuronium: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 21, 2025, https://www.rxlist.com/rocuronium/generic-drug.htm
11. Rocuronium - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539888/
12. pubchem.ncbi.nlm.nih.gov, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Rocuronium-Bromide#:~:text=Rocuronium%20bromide%20is%20the%20organic,and%20a%20quaternary%20ammonium%20salt.
13. Rocuronium Bromide | C32H53BrN2O4 | CID 441351 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Rocuronium-Bromide
14. Showing BioInteractions for Rocuronium (DB00728) | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00728/biointeractions
15. What is Rocuronium Bromide used for? - Patsnap Synapse, accessed July 21, 2025, https://synapse.patsnap.com/article/what-is-rocuronium-bromide-used-for
16. Definition of rocuronium bromide - NCI Drug Dictionary, accessed July 21, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rocuronium-bromide
17. Rocuronium: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00728
18. A new and efficient method for the synthesis of rocuronium bromide, accessed July 21, 2025, http://www.ccspublishing.org.cn/article/doi/10.1016/j.cclet.2016.10.026?pageType=en&viewType=HTML
19. A new and efficient method for the synthesis of rocuronium bromide, accessed July 21, 2025, http://www.ccspublishing.org.cn/article/doi/10.1016/j.cclet.2016.10.026?pageType=en
20. Generic ROCURONIUM BROMIDE INN entry, pharmaceutical patent expiry and freedom to operate - DrugPatentWatch, accessed July 21, 2025, https://www.drugpatentwatch.com/p/generic/rocuronium+bromide
21. A new and efficient method for the synthesis of rocuronium bromide - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/309531925_A_new_and_efficient_method_for_the_synthesis_of_rocuronium_bromide
22. patents.google.com, accessed July 21, 2025, https://patents.google.com/patent/US7569687B2/en#:~:text=The%20process%20for%20preparing%20rocuronium,mixture%3B%20and%20isolating%20rocuronium%20bromide.
23. What is the mechanism of Rocuronium Bromide? - Patsnap Synapse, accessed July 21, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-rocuronium-bromide
24. www.pfizermedicalinformation.com, accessed July 21, 2025, https://www.pfizermedicalinformation.com/rocuronium-bromide-injection/clinical-pharmacology#:~:text=Rocuronium%20bromide%20is%20a%20nondepolarizing,such%20as%20neostigmine%20and%20edrophonium.
25. Rocuronium bromide (NDC 0409-9558-05 and 0409-9558-10) Clinical Pharmacology, accessed July 21, 2025, https://www.pfizermedicalinformation.com/rocuronium-bromide-injection/clinical-pharmacology
26. Rocuronium dosing, indications, interactions, adverse effects, and more - Medscape, accessed July 21, 2025, https://reference.medscape.com/drug/zemuron-rocuronium-343109
27. Study Details | Pharmacokinetic and Pharmacodynamic of Rocuronium | ClinicalTrials.gov, accessed July 21, 2025, https://clinicaltrials.gov/study/NCT02376595
28. The Development and Regulatory History of Sugammadex in the United States, accessed July 21, 2025, https://www.apsf.org/article/the-development-and-regulatory-history-of-sugammadex-in-the-united-states/
29. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure | European Journal of Anaesthesiology - Cambridge University Press, accessed July 21, 2025, https://www.cambridge.org/core/journals/european-journal-of-anaesthesiology/article/pharmacokinetics-and-pharmacodynamics-of-rocuronium-in-patients-with-and-without-renal-failure/8161C6FDCB9D787C93FF4E9F1C971FDC
30. Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery | Journal of Pharmacy and Pharmacology | Oxford Academic, accessed July 21, 2025, https://academic.oup.com/jpp/article/68/11/1351/6128155
31. Clinical Pharmacology of Rocuronium in Infants and Children - Auctores | Journals, accessed July 21, 2025, https://www.auctoresonline.org/article/clinical-pharmacology-of-rocuronium-in-infants-and-children
32. Rocuronium Dosing by Ideal vs Total Body Weight in Obesity, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10777192/
33. The dosage of muscle relaxants in morbidly obese patients in daily ..., accessed July 21, 2025, https://www.dovepress.com/the-dosage-of-muscle-relaxants-in-morbidly-obese-patients-in-daily-pra-peer-reviewed-fulltext-article-IJGM
34. Rocuronium bromide, solution for injection, 10 mg/mL - NEW ZEALAND DATA SHEET, accessed July 21, 2025, https://www.medsafe.govt.nz/profs/datasheet/r/rocuroniumbromideinj.pdf
35. Rocuronium Advanced Patient Information - Drugs.com, accessed July 21, 2025, https://www.drugs.com/cons/rocuronium.html
36. Rocuronium dosing, indications, interactions, adverse effects, and more, accessed July 21, 2025, https://reference.medscape.com/drug/rocuronium-343109
37. Comparative study of rocuronium, vecuronium and succinylcholine for, accessed July 21, 2025, https://www.researchgate.net/publication/266277814_Comparative_study_of_rocuronium_vecuronium_and_succinylcholine_for_rapid_sequence_induction_of_anaesthesia
38. Rocuronium Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 21, 2025, https://www.drugs.com/sfx/rocuronium-side-effects.html
39. Rocuronium (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/rocuronium-intravenous-route/description/drg-20137750
40. e21db7bf-3cab-4000-94dd-15c6d2a213de.xml - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/spl/data/e21db7bf-3cab-4000-94dd-15c6d2a213de/e21db7bf-3cab-4000-94dd-15c6d2a213de.xml
41. FDA adds “black box” warning label to fluoroquinolone antibiotics - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2483892/
42. Rocuronium: Muscle Relaxant Uses, Side Effects, Dosage, accessed July 21, 2025, https://www.medicinenet.com/rocuronium/article.htm
43. Interactions of volatile anaesthetics with rocuronium bromide in perspective - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/7925200/
44. Rocuronium bromide (NDC 0409-9558-05 and 0409-9558-10 ..., accessed July 21, 2025, https://www.pfizermedical.com/rocuronium-bromide-injection/drug-interactions
45. www.pfizermedical.com, accessed July 21, 2025, https://www.pfizermedical.com/rocuronium-bromide-injection/drug-interactions#:~:text=Drugs%20which%20may%20enhance%20the,colistin%3B%20and%20sodium%20colistimethate)..&sa=D&source=editors&ust=1753093693072533&usg=AOvVaw3L8DVW1F1uBfKOotdDU22e)
46. Rocuronium and tobramycin Interactions - Drugs.com, accessed July 21, 2025, https://www.drugs.com/drug-interactions/rocuronium-with-tobramycin-2025-0-2206-0.html
47. Drug Interactions for Rocuronium Bromide - 15 Major Interactions - PrescriberPoint, accessed July 21, 2025, https://prescriberpoint.com/therapies/rocuronium-bromide-309aeb1/interactions
48. Therapeutic paralysis - EMCrit Project, accessed July 21, 2025, https://emcrit.org/ibcc/paralysis/
49. Succinylcholine Chloride - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK499984/
50. A Compari`Tive Study between Vecuronium and Rocuronium for Intubating Condition and Hemodynamic Changes - IOSR Journal, accessed July 21, 2025, https://www.iosrjournals.org/iosr-jdms/papers/Vol13-issue6/Version-1/H013613339.pdf
51. Efficacy and Safety of Rocuronium and Vecuronium with Respect to ..., accessed July 21, 2025, https://globalresearchonline.net/ijpsrr/v84-7/26.pdf
52. Comparison of effects of rocuronium bromide versus vecuronium bromide on hemodynamic parameters during anaesthesia for elective surgical procedures, accessed July 21, 2025, https://www.ijbcp.com/index.php/ijbcp/article/view/255
53. Federal Register, Volume 59 Issue 178 (Thursday, September 15, 1994) - GovInfo, accessed July 21, 2025, https://www.govinfo.gov/content/pkg/FR-1994-09-15/html/94-22760.htm
54. Bridion (sugammadex) FDA Approval History - Drugs.com, accessed July 21, 2025, https://www.drugs.com/history/bridion.html
55. ROCURONIUM BROMIDE - Pfizer, accessed July 21, 2025, https://www.pfizer.com/products/product-detail/rocuronium_bromide
56. Label: ROCURONIUM BROMIDE injection - DailyMed, accessed July 21, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d3a172a5-01ab-47d8-92ac-a8539b1d4dc4